Fat loss and metabolic health
Tirzepatide
The dual incretin hammer for weight loss.
Tirzepatide has very strong human data for obesity and diabetes. It is one of the rare peptide-adjacent compounds where the clinical evidence is louder than the influencer anecdotes.
Mechanism
What it probably does
Tirzepatide activates GIP and GLP-1 receptor pathways, driving appetite reduction and improved glucose handling.
Claims vs data
Where people get carried away
The data is strong. The main risk is people treating it like a shortcut instead of a protocol that needs protein, resistance training, labs, and exit planning.
Why people use it
- •large weight loss
- •type 2 diabetes
- •appetite control
- •metabolic syndrome
What to track
- •weight trend
- •waist
- •DEXA or body composition
- •fasting glucose
- •HbA1c
- •training performance
- •testosterone
- •thyroid markers
In Short
Tirzepatide is not bro-science. The bro-science starts when people ignore lean mass.
Appetite control is powerful. Appetite annihilation needs supervision.
Scientific evidence
Receipts before stories.
Anecdotal evidence
Not proof. Still useful signal.
Kabal angle
If you experiment, make the data impossible to ignore.
Kabal is built for the part most peptide pages skip: tracking the outcome, the dose, the timing, and the biomarkers that tell you whether the story holds up.
Get Kabal for iOS